Ten Queries And Replies To Raltegravir

Acknowledgments This article was presented at 17th Seoul International Symposium, Korean Society of Obstetrics and Gynecology, October four, 2012, and supported by a grant of your Korean Health Engineering R&D Project, Ministry 7 Answers And Inquiries To Paclitaxel of Health & Welfare, Republic of Korea (A111550).
Among malignant tumors in Korean women, cervical cancers have been reported as the fifth most common form of cancer after breast, stomach, colorectal, and thyroid cancers [1]. Recently, however, the occurrence of cervical cancer has decreased as it takes considerable amount of time to develop invasive cancers through a progress of dysplasia and intraepithelial carcinoma, and early detection of precancerous lesions is readily available due to periodic screening and the development of cervical cancer examination methods utilizing colpos copy and human papillomavirus (HPV) tests [2].

Pap smears are the most frequently utilized method for cervical cancer screening. The Pap smear technique was first developed by Papanicolaou and Taut [3], in 1941, and although it is a convenient, inexpensive, and safe method for cervical cancer screening, the rate of false negative errors is between 6% and 55%. In order to improve upon this error rate, liquid-based Pap Several Answers And Concerns To Paclitaxel [4], colposcopy, and human papillomavirus tests have been suggested as alternative screening methods [5]. Likewise, 'The Bethesda System' (TBS) was established by the National Cancer Institute meeting, held in Bethesda, USA in 1988, to address problems regarding diagnostic classification of Pap smear results.

Currently, a variety of classification Seven Solutions And Inquires To DOCK9 methods are utilized around the world, especially in the US. Specifically, atypical squamous cells of undetermined significance (ASCUS) and atypical glandular cells of undetermined significance (AGUS) are among the most important characteristics of TBS. According to TBS, ASCUS is defined as foremost by abnormal cells observed are worse than either reparative or reactive cells, and secondly as cells that do not satisfy the quantitative and qualitative criteria of squamous intraepithelial lesions [6], where AGUS are defined as those cells that satisfy the range of positive reactive changes but are not enough sufficient to be diagnosed as invasive adenocarcinomas [7].

In 2001, the Bethesda III classification, the terminology of both ASCUS and AGUS, were updated as ASC and atypical glandular cell (AGC), respectively; where ASC is subdivided into ASC-US and ASC-H while AGUS is subdivided into AGC-not otherwise specified (NOS) and AGC-favor neoplastic, respectively, and are now utilized in clinical diagnoses [8]. ASCUS findings accounts for 3% to 5% of Pap smear results, although this figure has been reported to vary between 10% to 20% and 3% to 5% on the diagnosed patients possessed the risk of cervical intraepithelial neoplasia (CIN)1 and CIN2 or CIN3, respectively.